News


All series


All News

William B. Donnellan, MD, was recently promoted to director of Leukemia/Myelodysplastic Syndrome Research at the Sarah Cannon Research Institute in Nashville, Tennessee. Donnellan has served as an investigator of hematologic malignancies since 2014 at the Sarah Cannon Research Institute.

Bert H. O&rsquo;Neil, MD, recently shared his considerations for treatment when treating patients with gastrointestinal cancers. O&rsquo;Neil reviewed how he would treat patients with colon cancer and patients with hepatocellular carcinoma based on case scenarios during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.<br /> &nbsp;

The combination of&nbsp;the BRAF inhibitor encorafenib (Braftovi) and the MEK inhibitor binimetinib (Mektovi) has been approved by the FDA&nbsp;for the treatment of patients with<em>&nbsp;BRAF</em>-mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.&nbsp;The approval is based data from the phase III COLUMBUS trial.

The anticancer immunotherapy vaccine SL-701, when used with immunostimulants, induced antitumor activity in patients with relapsed/refractory glioblastoma both alone and in combination with bevacizumab, according to updated phase II results from the 2-stage STML-701-0114 trial presented at the 2018 ASCO Annual Meeting.

Overall survival was not improved with the combination of palbociclib and fulvestrant compared with&nbsp;fulvestrant and placebo in the phase III PALOMA-3 trial for patients with HR-positive, HER2-negative metastatic breast cancer who received prior endocrine therapy, according to Pfizer, the developer of the CDK4/6 inhibitor.

An overall response rate of 60% was induced with venetoclax (Venclexta) monotherapy in&nbsp;patients with poor-risk relapsed/refractory mantle cell lymphoma who were previously treated with&nbsp;a BTK inhibitor,&nbsp;according to results presented at the 2018 European Hematology Association Congress.&nbsp;Of the responding patients, 20% had a complete response.

According to long-term follow-up data from the phase III CLL11 study, treatment with obinutuzumab combined with chlorambucil&nbsp;reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-na&iuml;ve patients with chronic lymphocytic leukemia with comorbidities. These findings were presented&nbsp;at the 2018 European Hematology Association Congress.

A&nbsp;supplemental biologics license application has been accepted by the FDA seeking approval for&nbsp;the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non&ndash;small cell lung cancer with tumor mutational burden&nbsp; &ge;10 mutations per megabase, according to Bristol-Myers Squibb, the manufacturer of both immune checkpoint inhibitors.

John Marshall, MD, recently shared the treatment considerations and decisions he makes when treating patients with gastrointestinal (GI) cancers. Marshal, chief of the Division of Hematology/Oncology, director of the Otto J. Ruesch Center for the Cure of GI Cancer, Medstar Georgetown University Hospital, in Washington, DC, explained his treatment decisions based on a case scenario during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

The FDA has added PD-L1 status to the&nbsp;labels for pembrolizumab (Keytruda) and atezolizumab (Tecentriq) for existing frontline approvals for platinum-ineligible patients with urothelial carcinoma. The addition was made&nbsp;based on lower overall survival rates with the PD-1/PD-L1 inhibitors compared with platinum-based chemotherapy for patients with PD-L1&ndash;low expressing platinum-eligible urothelial carcinoma.

The 16-gene Leukemic-MCL16 (L-MCL16) Assay reliably distinguished between classic and indolent mantle cell lymphoma subtypes in patients with leukemic presentation, according to results published in <em>Blood</em>. Combined with genomic complexity, the assay was prognostic for overall survival.

Based on survival data from the phase III TOWER study, blinatumomab has been granted full marketing authorization by the&nbsp;European Commission for&nbsp;the treatment of adult patients with Philadelphia&nbsp;chromosome-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia,&nbsp;according to Amgen, the developer of the anti-CD19 immunotherapy.

The biggest clinical unmet need in the treatment of patients with mantle cell lymphoma is overcoming resistance to BTK inhibitors, as patients who progress on treatment with ibrutinib&nbsp;(Imbruvica) and acalabrutinib (Calquence) are often incurable, according to Michael Wang, MD. Investigators are now challenged to find a new avenue of treatment.

An overall response rate of&nbsp;41.6% (95% CI, 32.9-50.8) was induced with the use of ivosidenib in patients with&nbsp;<em>IDH1</em>-positive relapsed/refractory acute myeloid leukemia, according to data presented at the 2018 ASCO Annual Meeting&nbsp;and published simultaneously online in the <em>New England Journal of Medicine</em>.

Yelena Y. Janjigian, MD, has been appointed chief of the Gastrointestinal Medical Oncology Service in the Division of Solid Tumor Oncology, Department of Medicine at Memorial Sloan Kettering Cancer Center in New York. She will succeed Leonard Saltz, MD, who had held this position for 5 years. Saltz will assume the position of executive director for clincal value and sustainability.